<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02064413</url>
  </required_header>
  <id_info>
    <org_study_id>17069</org_study_id>
    <nct_id>NCT02064413</nct_id>
  </id_info>
  <brief_title>Essure (Model ESS310) Placement Rate Study</brief_title>
  <official_title>A Multi-Center, United States Clinical Study to Evaluate Placement Success of the ESS310 Essure® System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and successful placement rate of Essure Model ESS310 device and any&#xD;
      factors that may influence the successful placement rate of this device.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 17, 2014</start_date>
  <completion_date type="Actual">November 26, 2014</completion_date>
  <primary_completion_date type="Actual">October 2, 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of successful bilateral placement of the ESS310 insert at first attempt in subjects who undergo attempted ESS310 placement</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Successful bilateral placement rate of the ESS310 insert at first attempt in all subjects who undergo hysteroscopy with the intent of having bilateral ESS310 placement</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of investigator questionnaire regarding ESS310 design and usability</measure>
    <time_frame>Day 1</time_frame>
    <description>Potential aspects of the ESS310 design and usability that may impact bilateral placement rate at first attempt</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of investigator questionnaire regarding potential factors predictive of failure to achieve bilateral placement of the ESS310 insert at first attempt</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hysteroscopy time to perform the procedure</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Adverse device effects (ADE) as a measure of safety and tolerability</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Adverse procedure-related events as a measure of safety and tolerability</measure>
    <time_frame>Day 1, 1 week</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">134</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>ESS310</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects that sign the informed consent and meet the eligibility criteria will be scheduled for an implant procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ESS310 (BAY1454032)</intervention_name>
    <arm_group_label>ESS310</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Females aged range 21 to 44 years&#xD;
&#xD;
          -  Subjects seeking permanent contraception&#xD;
&#xD;
          -  Subjects with body weight within range of 90-300 pounds (40 - 136 kilograms)&#xD;
&#xD;
          -  Subjects for whom medical history indicates bilateral viable and patent fallopian&#xD;
             tubes&#xD;
&#xD;
          -  Subjects are able and willing to comply with the protocol required follow-up visits&#xD;
&#xD;
          -  Subjects have fulfilled local requirements for counseling and consent to contraception&#xD;
             and sterilization, including any required waiting periods&#xD;
&#xD;
          -  Subjects provide written informed consent prior to enrolment&#xD;
&#xD;
          -  Subjects who have sufficient mental capacity to understand the informed consent form&#xD;
             (ICF), comply with the protocol requirements, and provide clinically relevant and&#xD;
             reliable feedback regarding their experience implant and subsequent wearing of the&#xD;
             device&#xD;
&#xD;
          -  Subjects who agree that anonymized personal data will be made available to study&#xD;
             Sponsor and requisite regional and international regulatory bodies&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects suspected of being or confirmed pregnant&#xD;
&#xD;
          -  Subjects post-partum or undergone pregnancy termination ≤6 weeks of scheduled insert&#xD;
             placement&#xD;
&#xD;
          -  Subjects who have known proximal tubal occlusion in either fallopian tube&#xD;
&#xD;
          -  Subjects who have undergone fallopian tube sterilization procedure&#xD;
&#xD;
          -  Subjects who have had total or partial salpingectomies&#xD;
&#xD;
          -  Subjects diagnosed with tubal, endometrial, or myometrial pathology which may prevent&#xD;
             fallopian tube ostia access&#xD;
&#xD;
          -  Subjects diagnosed with unicornuate uterus&#xD;
&#xD;
          -  Subjects diagnosed with active or currently being treated upper or lower pelvic&#xD;
             infection&#xD;
&#xD;
          -  Subjects with gynecologic malignancy&#xD;
&#xD;
          -  Subjects who are currently taking corticosteroids&#xD;
&#xD;
          -  Subjects with a known allergy to all contrast media available for use in HSG&#xD;
             (Hysterosalpingogram)&#xD;
&#xD;
          -  Subjects scheduled to undergo concomitant intrauterine procedures at the time of&#xD;
             insert placement (e.g., endometrial ablation, fibroid resection by hysteroscopy,&#xD;
             endometrial polypectomy). Intrauterine device removal is not considered a concomitant&#xD;
             procedure.&#xD;
&#xD;
          -  Subjects with any general health condition or systemic disease that may represent, in&#xD;
             the opinion of the physician, a potential increased risk associated with device use or&#xD;
             pregnancy&#xD;
&#xD;
          -  Subjects with a close affiliation with the investigational site, e.g. closely related&#xD;
             or affiliated with the investigator (such as dependent, employee or student of the&#xD;
             investigational site, or sponsor's staff)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80923</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newburgh</city>
        <state>Indiana</state>
        <zip>47630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Grand Blanc</city>
        <state>Michigan</state>
        <zip>48439</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saginaw</city>
        <state>Michigan</state>
        <zip>48604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University Physicians Group</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <zip>48034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45409-2793</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Women's Care, PC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.bayer.com/</url>
    <description>Click here to find results for studies related to Bayer Healthcare products.</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 14, 2014</study_first_submitted>
  <study_first_submitted_qc>February 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2014</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Birth control</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

